Orexigen marks $1.33 million operating loss for March 12 to March 31

By Caroline Salls

Pittsburgh, May 4 – Orexigen Therapeutics, Inc. reported a $1.33 million loss from operations for the period of March 12 through March 31 on $6.03 million in net product sales, according to its monthly operating report filed Friday with the Securities and Exchange Commission.

The net loss for the period was $168.98 million, including $167.58 million in reorganization expenses.

The company had $14.68 million in cash and cash equivalents as of March 31.

Orexigen is a San Diego-based biopharmaceutical company focused on the treatment of obesity. The company filed for bankruptcy on March 12 in the U.S. Bankruptcy Court for the District of Delaware under Chapter 11 case number 18-10518.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.